P/E ratio for Enzo Biochem (ENZ)
P/E ratio as of April 2024 (TTM): -1.13
According to Enzo Biochem's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.12766. At the end of 2022 the company had a P/E ratio of -2.60.
P/E ratio history for Enzo Biochem from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -2.60 | -108.1% |
| 2021 | 32.1 | -647.74% |
| 2020 | -5.86 | -104.46% |
| 2019 | 132 | -1660.97% |
| 2018 | -8.42 | -96.95% |
| 2017 | -276 | -3482.81% |
| 2016 | 8.16 | -74.6% |
| 2015 | 32.1 | -280.98% |
| 2014 | -17.8 | 167.62% |
| 2013 | -6.64 | 143.33% |
| 2012 | -2.73 | -47.65% |
| 2011 | -5.21 | -43.76% |
| 2010 | -9.26 | -13.91% |
| 2009 | -10.8 | -5.38% |
| 2008 | -11.4 | -67.87% |
| 2007 | -35.4 | 6.64% |
| 2006 | -33.2 | -35.87% |
| 2005 | -51.8 | -105.32% |
| 2004 | 973 | -170.02% |
| 2003 | < -1000 | -3193.47% |
| 2002 | 44.9 | -51.43% |
| 2001 | 92.5 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Quest Diagnostics
DGX | 20.3 | -1,904.41% | 🇺🇸 USA |
 LabCorp LH | 27.7 | -2,552.12% | 🇺🇸 USA |
 RadNet RDNT | -212 | 18,665.32% | 🇺🇸 USA |
 Psychemedics PMD | -7.75 | 587.64% | 🇺🇸 USA |
 NeoGenomics
NEO | -15.3 | 1,252.36% | 🇺🇸 USA |
 Qiagen QGEN | 28.6 | -2,631.97% | 🇳🇱 Netherlands |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.